186 related articles for article (PubMed ID: 31536953)
1. Novel 2-arylthiopropanoyl-CoA inhibitors of α-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.
Yevglevskis M; Nathubhai A; Wadda K; Lee GL; Al-Rawi S; Jiao T; Mitchell PJ; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Bioorg Chem; 2019 Nov; 92():103263. PubMed ID: 31536953
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel small-molecule inhibitors of α-methylacyl-CoA racemase (AMACR; P504S) and structure-activity relationships.
Petrova YD; Wadda K; Nathubhai A; Yevglevskis M; Mitchell PJ; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Bioorg Chem; 2019 Nov; 92():103264. PubMed ID: 31536955
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of rationally designed AMACR 1A inhibitors.
Yevglevskis M; Lee GL; Nathubhai A; Petrova YD; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Bioorg Chem; 2018 Sep; 79():145-154. PubMed ID: 29751320
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human α-methylacyl CoA racemase (AMACR): a target for prostate cancer.
Carnell AJ; Kirk R; Smith M; McKenna S; Lian LY; Gibson R
ChemMedChem; 2013 Oct; 8(10):1643-7. PubMed ID: 23929631
[TBL] [Abstract][Full Text] [Related]
5. A novel colorimetric assay for α-methylacyl-CoA racemase 1A (AMACR; P504S) utilizing the elimination of 2,4-dinitrophenolate.
Yevglevskis M; Lee GL; Nathubhai A; Petrova YD; James TD; Threadgill MD; Woodman TJ; Lloyd MD
Chem Commun (Camb); 2017 May; 53(37):5087-5090. PubMed ID: 28338138
[TBL] [Abstract][Full Text] [Related]
6. Trifluoroibuprofen inhibits α-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models.
Festuccia C; Gravina GL; Mancini A; Muzi P; Cesare ED; Kirk R; Smith M; Hughes S; Gibson R; Lian LY; Ricevuto E; Carnell AJ
Anticancer Agents Med Chem; 2014; 14(7):1031-41. PubMed ID: 24712326
[TBL] [Abstract][Full Text] [Related]
7. A study on the AMACR catalysed elimination reaction and its application to inhibitor testing.
Yevglevskis M; Lee GL; Sun J; Zhou S; Sun X; Kociok-Köhn G; James TD; Woodman TJ; Lloyd MD
Org Biomol Chem; 2016 Jan; 14(2):612-622. PubMed ID: 26537174
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and in vitro testing of alpha-methylacyl-CoA racemase inhibitors.
Carnell AJ; Hale I; Denis S; Wanders RJ; Isaacs WB; Wilson BA; Ferdinandusse S
J Med Chem; 2007 May; 50(11):2700-7. PubMed ID: 17477519
[TBL] [Abstract][Full Text] [Related]
9. New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors.
Morgenroth A; Urusova EA; Dinger C; Al-Momani E; Kull T; Glatting G; Frauendorf H; Jahn O; Mottaghy FM; Reske SN; Zlatopolskiy BD
Chemistry; 2011 Aug; 17(36):10144-50. PubMed ID: 21812041
[TBL] [Abstract][Full Text] [Related]
10. α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S.
Lloyd MD; Yevglevskis M; Lee GL; Wood PJ; Threadgill MD; Woodman TJ
Prog Lipid Res; 2013 Apr; 52(2):220-30. PubMed ID: 23376124
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S).
Wilson BA; Wang H; Nacev BA; Mease RC; Liu JO; Pomper MG; Isaacs WB
Mol Cancer Ther; 2011 May; 10(5):825-38. PubMed ID: 21441411
[TBL] [Abstract][Full Text] [Related]
12. Analysis of enzyme reactions using NMR techniques: A case study with α-methylacyl-CoA racemase (AMACR).
Woodman TJ; Lloyd MD
Methods Enzymol; 2023; 690():159-209. PubMed ID: 37858529
[TBL] [Abstract][Full Text] [Related]
13. Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Zhou M; Jiang Z; Epstein JI
Am J Surg Pathol; 2003 Jun; 27(6):772-8. PubMed ID: 12766580
[TBL] [Abstract][Full Text] [Related]
14. The perils of rational design--unexpected irreversible elimination of fluoride from 3-fluoro-2-methylacyl-CoA esters catalysed by α-methylacyl-CoA racemase (AMACR; P504S).
Yevglevskis M; Lee GL; Threadgill MD; Woodman TJ; Lloyd MD
Chem Commun (Camb); 2014 Nov; 50(91):14164-6. PubMed ID: 25277991
[TBL] [Abstract][Full Text] [Related]
15. Potent dialkyl substrate-product analogue inhibitors and inactivators of α-methylacyl-coenzyme A racemase from Mycobacterium tuberculosis by rational design.
Pal M; Easton NM; Yaphe H; Bearne SL
Bioorg Chem; 2018 Apr; 77():640-650. PubMed ID: 29502025
[TBL] [Abstract][Full Text] [Related]
16. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Wu CL; Yang XJ; Tretiakova M; Patton KT; Halpern EF; Woda BA; Young RH; Jiang Z
Hum Pathol; 2004 Aug; 35(8):1008-13. PubMed ID: 15297968
[TBL] [Abstract][Full Text] [Related]
17. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
[TBL] [Abstract][Full Text] [Related]
18. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Kunju LP; Chinnaiyan AM; Shah RB
Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196
[TBL] [Abstract][Full Text] [Related]
19. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
20. Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
Mobley JA; Leav I; Zielie P; Wotkowitz C; Evans J; Lam YW; L'Esperance BS; Jiang Z; Ho SM
Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):775-83. PubMed ID: 12917210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
